A small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) studied in laboratory models of adipocyte metabolism and cellular energy pathways.
🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule quinolinium compound, not a peptide. It is studied as a selective inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT).
Because NNMT is implicated in cellular metabolism and NAD+ salvage pathways, this compound is a subject of research in metabolic and longevity-related cell models.
5-Amino-1MQ inhibits NNMT, an enzyme that methylates nicotinamide using S-adenosylmethionine. In cell models, NNMT inhibition is associated with altered nicotinamide and NAD+ handling and changes in cellular methylation capacity.
Research explores how these shifts affect adipocyte energy metabolism and related pathways.
NNMT inhibition — characterized in enzymatic and cellular assays of methyltransferase activity [1].
Adipocyte metabolism — studied in fat-cell models measuring cellular energy and lipid handling [2].
NAD+ and methylation pathways — investigated for effects on NAD+ salvage and methyl-donor pools [1].
Body composition models — examined in rodent studies of diet-induced obesity [2].
📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.
In enzyme and cell-based assays, researchers applied 5-Amino-1MQ and measured NNMT activity and downstream nicotinamide metabolism [1]. In a diet-induced obesity mouse study, animals received the compound and investigators measured changes in body weight and adipose tissue [2].
Additional cell studies assessed effects on adipocyte differentiation and cellular NAD+ levels [1].
Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.
NAD+ precursors (NMN/NR)Synergistic
Researchers study NNMT inhibition alongside NAD+ precursor pathways for combined effects on NAD+ pools.
SemaglutideNeutral
Distinct mechanism (NNMT vs GLP-1); no established combined pharmacology.
MOTS-cCompatible
Both feature in mitochondrial/metabolic research contexts, though direct interaction data are limited.
MetforminNeutral
Both studied in metabolic models; interaction not well characterized.
Citations below are retrieved automatically from PubMed (NIH / U.S. National Library of Medicine) for the search term “5-Amino-1MQ”, newest first. They are listed as literature references for research purposes only. K4 Elite does not summarise, interpret or endorse their findings.
No. It is a small-molecule quinolinium compound that inhibits the enzyme NNMT.
What is NNMT?
Nicotinamide N-methyltransferase, an enzyme involved in nicotinamide methylation and linked to NAD+ and metabolic pathways.
What has it been studied for?
Research covers NNMT inhibition, adipocyte metabolism, NAD+/methylation pathways, and body composition in rodent models.
Is this material for human use?
No. It is supplied for in-vitro and laboratory research use only, not for human or veterinary use.
Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.
K4 Elite